Compare VBNK & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VBNK | ATAI |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.8M | 1.4B |
| IPO Year | 2021 | 2021 |
| Metric | VBNK | ATAI |
|---|---|---|
| Price | $14.41 | $4.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $13.00 | ★ $14.00 |
| AVG Volume (30 Days) | 48.3K | ★ 3.6M |
| Earning Date | 12-10-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $85,792,576.00 | $3,018,000.00 |
| Revenue This Year | $36.55 | $943.83 |
| Revenue Next Year | $29.23 | N/A |
| P/E Ratio | $22.58 | ★ N/A |
| Revenue Growth | 7.44 | ★ 811.78 |
| 52 Week Low | $8.51 | $1.15 |
| 52 Week High | $16.43 | $6.75 |
| Indicator | VBNK | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 83.84 | 49.78 |
| Support Level | $11.88 | $4.25 |
| Resistance Level | $14.69 | $4.54 |
| Average True Range (ATR) | 0.43 | 0.22 |
| MACD | 0.25 | 0.10 |
| Stochastic Oscillator | 90.53 | 71.36 |
VersaBank is a Canadian Schedule I chartered bank with a difference. It has 3 operating segments: Digital Banking Canada, Digital Banking USA and DRTC. It's, cloud-based, business-to-business deposit and lending model provides valued-added solutions to Canadian financial intermediary partners, enabling them to focus on growing their own businesses faster and more profitably. It obtains all of its deposits and provides the majority of its loans and leases electronically, with deposit and lending solutions for financial intermediaries that allow them to excel in their core businesses. In addition, leveraging its internally developed IT security software and capabilities, Company established a wholly owned, subsidiary. Geographically located in Canada and USA.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.